Subtype
Female Reproductive System Carcinoma
CI-CAN-00002685Explore in graph →
458 active trials5 approved drugs36 evidence items
- NCIt
- C181162
Loading cancer entity…
Subtype
CI-CAN-00002685Explore in graph →
Clinical trials
1,481 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00182767 | Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer | completed | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2016 | clinicaltrials |
| NCT01709487 | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy | completed | Phase 1 / Phase 2 | 19 | Jules Bordet InstituteOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer(GeparSixto) | completed | Phase 2 / Phase 3 | 595 | GBG Forschungs GmbHOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT01238770 | Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 10 | Priv.-Doz. Dr. med. Joachim RomOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT00390234 | Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 2 | Dec 7, 2015 | clinicaltrials |
| NCT00059787 | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Dec 1, 2015 | clinicaltrials |
| NCT00057863 | Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2015 | clinicaltrials |
| NCT00275028 | AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Nov 9, 2015 | clinicaltrials |
| NCT01026792 | Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery | completed | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2015 | clinicaltrials |
| NCT00421889 | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | completed | Phase 1 / Phase 2 | 80 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00100841 | Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer | completed | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00217633 | Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer | completed | Phase 2 | 38 | Gynecologic Oncology GroupNETWORK | 2 | May 29, 2015 | clinicaltrials |
| NCT00072566 | Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | May 12, 2015 | clinicaltrials |
| NCT00072176 | Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2015 | clinicaltrials |
| NCT01815528 | Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer | completed | Phase 2 | 2 | JSehouliOTHER | 1 | Feb 18, 2015 | clinicaltrials |
| NCT00389974 | Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Feb 16, 2015 | clinicaltrials |
| NCT00388037 | Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2015 | clinicaltrials |
| NCT00499031 | Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 38 | Gynecologic Oncology GroupNETWORK | 1 | Jan 13, 2015 | clinicaltrials |
| NCT00868192 | Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | completed | Phase 2 | 38 | Washington University School of MedicineOTHER | 1 | Oct 20, 2014 | clinicaltrials |
| NCT01481701 | A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma | completed | Phase 2 | 90 | Jules Bordet InstituteOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT00183794 | Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma | completed | Phase 2 | 20 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00083122 | Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00093496 | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer | completed | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | May 20, 2014 | clinicaltrials |
| NCT00126542 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT01079832 | Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies | completed | Phase 2 | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2013 | clinicaltrials |
| NCT00721890 | Green Tea Intake for the Maintenance of Complete Remission in Women With Advanced Ovarian Carcinoma(DBGT-OC-CR) | completed | Phase 2 | 16 | CHU de Quebec-Universite LavalOTHER | 1 | Oct 24, 2013 | clinicaltrials |
| NCT00677079 | Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 12 | SanofiINDUSTRY | 1 | Oct 1, 2013 | clinicaltrials |
| NCT01937650 | Radiotherapy + Metronidazole vs Radiotherapy Alone In Improving Treatment Outcomes in Advanced Cervical Cancer in Uganda | completed | Phase 2 / Phase 3 | 38 | Makerere UniversityOTHER | 0 | Sep 9, 2013 | clinicaltrials |
| NCT00006942 | Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00096395 | Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jun 13, 2013 | clinicaltrials |
| NCT00026091 | Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00041041 | Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00025467 | Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00036751 | Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00081276 | 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00016289 | Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00031993 | Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00107445 | EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00063895 | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00861120 | Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type(PaLiDo) | completed | Phase 2 | 33 | Vejle HospitalOTHER | 4 | Oct 26, 2012 | clinicaltrials |
| NCT00563836 | Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer | completed | Phase 2 | 41 | Neovii BiotechINDUSTRY | 2 | Oct 3, 2012 | clinicaltrials |
| NCT00334295 | Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. | completed | Phase 2 | 35 | AstraZenecaINDUSTRY | 1 | Jul 31, 2012 | clinicaltrials |
| NCT00281515 | Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer | completed | Phase 2 | 105 | AGO Study GroupOTHER | 1 | Jun 29, 2012 | clinicaltrials |
| NCT00407563 | Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer | completed | Phase 2 | 48 | Accelerated Community Oncology Research NetworkOTHER | 1 | Apr 5, 2012 | clinicaltrials |
| NCT00561795 | Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors | completed | Phase 2 | 12 | GlaxoSmithKlineINDUSTRY | 2 | Mar 22, 2012 | clinicaltrials |
| NCT00316407 | Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients | completed | Phase 1 / Phase 2 | 30 | Swedish Medical CenterOTHER | 1 | Feb 18, 2011 | clinicaltrials |
| NCT00490711 | Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 7 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 25, 2007 | clinicaltrials |
Data updated 23 days agoSource updated Mar 10, 2016source: clinicaltrials